Organon & Co.
OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzysā¦ read more
Healthcare
Drug ManufacturersāGeneral
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.56
Price+0.07%
$0.01
1Y
Price
Market Cap
$3.561b
Mid
Price/Earnings 3y Avg5y Avg
4.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+20.7%
EBITDA Margin+6.9%
Net Profit Margin-12050.5%
Free Cash Flow Margin+20.7%
EBITDA Margin+6.9%
Net Profit Margin-12050.5%
Free Cash Flow MarginRevenue
$4.571b
-26.5%
1y CAGR-9.0%
3y CAGR-6.4%
5y CAGREarnings
$101.108m
-45.9%
1y CAGR-46.6%
3y CAGR-32.1%
5y CAGREPS
$0.77
+6.9%
1y CAGR-29.3%
3y CAGR-19.2%
5y CAGRBook Value
$1.006m
$13.178m
Assets$12.172m
Liabilities$8.553m
DebtDebt to Assets
64.9%
-
Debt to EBITDAFree Cash Flow
$245.253m
-54.4%
1y CAGR-17.9%
3y CAGR-7.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company